Skip to content

The Oncology Institute, Inc. TOI Operating lease liabilities

Operating lease liabilities at other companies

McKesson logo
McKessonMCK
-$68M+31.3%
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
Immunome logo
ImmunomeIMNM
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
Privia Health Group, Inc. logo
Privia Health Group, Inc.PRVA

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s operating lease liabilities?
The Oncology Institute, Inc. (TOI) reported operating lease liabilities of -$186K in Q1 2026.
How has The Oncology Institute, Inc.'s operating lease liabilities changed year-over-year?
The Oncology Institute, Inc.'s operating lease liabilities decreased by 14.8% year-over-year, from -$162K to -$186K.